The procedure is in progress.

With the support of Groupe Grimaud and trust of its customers and partners, Novogen will take of course any action to enforce its rights in court and challenge the accusations of Lohmann which are totally unfounded.

In any case, the technologies used by Novogen for the quantitative phenotypic selection do not fall within the scope of the patent registered by Lohmann.

It is through original and innovative approaches that within a few years the Novogen products have come to the highest level for productivity, behaviour, feed consumption and egg quality, allowing the company to be recognised and appreciated as a major actor in the field of layer genetics.

Frédéric Grimaud states: "I regret that competitors may run out of business arguments and therefore look for other actions with no other goal than trying to destabilise our company. It is clear that our entry into the layer market and the quality of our products bother them.

"We represent a serious threat to the historic duopoly of the two main primary breeders in the egg industry. We will not be impressed by any of these manoeuvres and continue to work closely with our customers to continue to offer the best products under the best conditions."

Novogen will and is continuing its development with professionalism and determination based on its three main pillars:

• A range of high performance products in both white, brown and tinted eggs
• Use of original and differentiating selection techniques
• A dedicated and passionate team.